Moleculin Biotech, Inc.
NASDAQ:MBRX
Overview | Financials
Company Name | Moleculin Biotech, Inc. |
Symbol | MBRX |
Currency | USD |
Price | 1.7 |
Market Cap | 5,424,530 |
Dividend Yield | 0% |
52-week-range | 0.4 - 6.24 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Walter V. Klemp |
Website | https://www.moleculin.com |
An error occurred while fetching data.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD